INMD Stock — InMode Ltd.

InMode Ltd. (INMD)

Updated October 16, 2026.

INMD is a Stock. Total return is 108.7% over the past 7.2 years, 79.9 points behind SPY at 188.6%.

InMode Ltd. designs and manufactures minimally invasive and non-invasive aesthetic medical devices based on proprietary radiofrequency technologies, serving procedures such as liposuction with skin tightening, body contouring, hair removal, and skin rejuvenation. The company sells its products globally through distributors across North America, Europe, Asia, and other markets. InMode does not currently have an established distribution to shareholders.

INMD performance versus SPY

Price and return data through 2026-10-16.

Total return is 108.7% over the past 7.2 years, 79.9 points behind SPY at 188.6%. Over the past year its total return — price change plus distributions reinvested — is -7.0%. Its deepest 1-year drawdown was 23.2%.

INMD key facts

Asset type

Stock

Asset class

Equity

Inception date

08/08/2019

Distribution frequency

None

Last close

$14.16 (as of 2026-10-16)

Market cap

$814,825,476

Average volume

417144.0

Beta

2.028

Payout ratio

0.0%

P/E ratio

11.7

Forward P/E

9.99

EPS

$1.21

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

INMD risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 23.2%.

Who may consider INMD — and who may not

It is a weaker fit for investors who need monthly cash flow (INMD does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on INMD

• All tickers starting with I

Tagged: Healthcare.

Frequently asked questions